Shazia Tayyab
Child & Adolescent Psychiatry · Libertyville, ILNPI 1871695932
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,299 and has fallen 82.8% since, to $224 in 2025. Among child & adolescent psychiatry clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$721
- AbbVie$513
- Sunovion Pharmaceuticals Inc.$407
- Otsuka America Pharmaceutical, Inc.$358
- Takeda Pharmaceuticals U.S.A., Inc.$352
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$291
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,856100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 52 | $721 |
| AbbVie(2 entities) | 21 | $513 |
| Sunovion Pharmaceuticals Inc. | 19 | $407 |
| Otsuka America Pharmaceutical, Inc. | 19 | $358 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $291 |
| Tris Pharma Inc | 17 | $290 |
| Ironshore Pharmaceuticals Inc. | 16 | $258 |
| Lundbeck LLC | 12 | $232 |
| Vanda Pharmaceuticals Inc. | 10 | $208 |
| Neurocrine Biosciences, Inc. | 8 | $203 |
| Neos Therapeutics, LP | 13 | $199 |
| Johnson & Johnson | 8 | $176 |
| Corium, LLC | 7 | $115 |
| Axsome Therapeutics, Inc. | 5 | $107 |
| Adlon Therapeutics L.p. | 7 | $102 |
| Shire North American Group Inc | 4 | $72 |
| Jazz Pharmaceuticals Inc. | 2 | $60 |
| Vertical Pharmaceuticals, LLC | 3 | $52 |
| Alkermes, Inc. | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Noven Therapeutics, LLC | 1 | $23 |
| Neuronetics, Inc. | 2 | $23 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$4,856 in reported general payments places this provider in the 90th percentile of 124 child & adolescent psychiatry providers in Illinois.
See all child & adolescent psychiatry providers in Illinois →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 14 | $206 |
| Olanzapine | 12 | $193 |
| Lamotrigine | 14 | $92 |
| Gabapentin | 13 | $50 |
| Duloxetine Hcl | 16 | $41 |
| Lorazepam | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Libertyville
- Fareha MalikElgin$57K
- Gregory TeasHoffman Estates$36K
- Martins AdeoyeOrland Park$10K
- Daniel MartinezLombard$8K
- Khalid ArshadKankakee$8K
- Talat GhausHinsdale$6K
- Walter PedemonteOak Park$5K
- Bradley PechterMelrose Park$5K
- Birju PatelKenilworth$5K
- Ing LamOrland Park$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.